Old Web
English
Sign In
Acemap
>
authorDetail
>
N. Pandit-Abid
N. Pandit-Abid
Dupilumab
Medicine
in patient
Asthma
Internal medicine
5
Papers
1
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (5)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Assessment of Long-Term Maintenance of OCS Reduction and Efficacy in the Dupilumab LIBERTY ASTHMA TRAVERSE Extension Study
2021
Lawrence Sher
Michael E. Wechsler
Klaus F. Rabe
J.F. Máspero
N. Daizadeh
X. Mao
Benjamin Ortiz
L.P. Mannent
E. Laws
Marcella Ruddy
N. Pandit-Abid
David Lederer
M.E Hardin
Show All
Source
Cite
Save
Citations (0)
Dupilumab Provides Rapid and Sustained Exacerbation Protection in Patients with Uncontrolled, Moderate-to-Severe Type 2 Inflammatory Asthma Enrolled in the LIBERTY ASTHMA QUEST Study
2021
Jonathan Corren
L. Rogers
Alberto Papi
Zhen Chen
N. Pandit-Abid
P. Rowe
Yamo Deniz
Benjamin Ortiz
Show All
Source
Cite
Save
Citations (0)
Dupilumab Reduced Oral Corticosteroid Use in Patients with OCS-Dependent Severe Asthma Consistently Across Baseline Disease Characteristics in the Phase 3 LIBERTY ASTHMA VENTURE Study
2020
M. Castro
Nicola A. Hanania
N. Daizadeh
B. Ortiz
N. Pandit-Abid
Y. Deniz
Paul Rowe
Show All
Source
Cite
Save
Citations (0)
Dupilumab Reduced Oral Corticosteroid (OCS) Use in Patients with OCS-Dependent, Severe Asthma Consistently Across Baseline Demographic Characteristics in the Phase 3 LIBERTY ASTHMA VENTURE Study
2020
Jorge Maspero
Linda B. Ford
N. Daizadeh
N. Pandit-Abid
B. Ortiz
Paul Rowe
Y. Deniz
Show All
Source
Cite
Save
Citations (0)
Dupilumab is associated with lower rates of respiratory infections in patients with chronic rhinosinusitis with nasal polyps-Safety analysis from the SINUS-52 phase 3 trial
2020
Allergy
Claus Bachert
Philippe Gevaert
Se Lee
N. Kanesa-Thasan
S. Green
Leda Mannent
Nikhil Amin
Zhen Chen
Xiang Lü
N. Pandit-Abid
Benjamin Ortiz
Show All
Source
Cite
Save
Citations (1)
1